Health-related quality of life in multiple sclerosis: effects of natalizumab
Version of Record online: 14 AUG 2007
Copyright © 2007 American Neurological Association
Annals of Neurology
Volume 62, Issue 4, pages 335–346, October 2007
How to Cite
Rudick, R. A., Miller, D., Hass, S., Hutchinson, M., Calabresi, P. A., Confavreux, C., Galetta, S. L., Giovannoni, G., Havrdova, E., Kappos, L., Lublin, F. D., Miller, D. H., O'Connor, P. W., Phillips, J. T., Polman, C. H., Radue, E.-W., Stuart, W. H., Wajgt, A., Weinstock-Guttman, B., Wynn, D. R., Lynn, F. and Panzara, M. A. (2007), Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol., 62: 335–346. doi: 10.1002/ana.21163
- Issue online: 29 OCT 2007
- Version of Record online: 14 AUG 2007
- Manuscript Accepted: 8 MAY 2007
- Manuscript Revised: 12 APR 2007
- Manuscript Received: 18 DEC 2006
- Biogen Idec
- Elan Pharmaceuticals
To report the relationship between disease activity and health-related quality of life (HRQoL) in relapsing multiple sclerosis, and the impact of natalizumab.
HRQoL data were available from 2,113 multiple sclerosis patients in natalizumab clinical studies. In the Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis (AFFIRM) study, patients received natalizumab 300mg (n = 627) or placebo (n = 315); in the Safety and Efficacy of Natalizumab in Combination with Interferon Beta-1a in Patients with Relapsing Remitting Multiple Sclerosis (SENTINEL) study, patients received interferon beta-1a (IFN-β-1a) plus natalizumab 300mg (n = 589), or IFN-β-1a plus placebo (n = 582). The Short Form-36 (SF-36) and a subject global assessment visual analog scale were administered at baseline and weeks 24, 52, and 104. Prespecified analyses included changes from baseline to week 104 in SF-36 and visual analog scale scores. Odds ratios for clinically meaningful improvement or worsening on the SF-36 Physical Component Summary (PCS) and Mental Component Summary were calculated.
Mean baseline SF-36 scores were significantly less than the general US population and correlated with Expanded Disability Status Scale scores, sustained disability progression, relapse number, and increased volume of brain magnetic resonance imaging lesions. Natalizumab significantly improved SF-36 PCS and Mental Component Summary scores at week 104 in AFFIRM. PCS changes were significantly improved by week 24 and at all subsequent time points. Natalizumab-treated patients in both studies were more likely to experience clinically important improvement and less likely to experience clinically important deterioration on the SF-36 PCS. The visual analog scale also showed significantly improved HRQoL with natalizumab.
HRQoL was impaired in relapsing multiple sclerosis patients, correlated with severity of disease as measured by neurological ratings or magnetic resonance imaging, and improved significantly with natalizumab. Ann Neurol 2007